KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Work In Process (2018 - 2020)

Historic Work In Process for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q1 2020 value amounting to $53.1 million.

  • Amneal Pharmaceuticals' Work In Process changed N/A to $53.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $53.1 million, marking a year-over-year change of. This contributed to the annual value of $58.2 million for FY2019, which is 745.31% up from last year.
  • According to the latest figures from Q1 2020, Amneal Pharmaceuticals' Work In Process is $53.1 million.
  • Over the past 5 years, Amneal Pharmaceuticals' Work In Process peaked at $58.2 million during Q4 2019, and registered a low of $50.8 million during Q3 2019.
  • Moreover, its 3-year median value for Work In Process was $53.6 million (2018), whereas its average is $54.0 million.
  • Over the last 5 years, Amneal Pharmaceuticals' Work In Process had its largest YoY gain of 745.31% in 2019, and its largest YoY loss of 745.31% in 2019.
  • Quarter analysis of 3 years shows Amneal Pharmaceuticals' Work In Process stood at $54.2 million in 2018, then grew by 7.45% to $58.2 million in 2019, then decreased by 8.79% to $53.1 million in 2020.
  • Its Work In Process was $53.1 million in Q1 2020, compared to $58.2 million in Q4 2019 and $50.8 million in Q3 2019.